Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy
Dropouts ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher dropouts ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
- Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes onlyRR 1.6 [1.01, 2.55]2 studies · 199 participantsModerate